T-Cell Sciences
Executive Summary
More than doubles cash balance with $18 mil. private placement of 2.8 mil. shares of common stock. U.S. and European institutional investors agreed to pay $6.35 per share; Wertheim Schroder arranged the transaction. T Cell will use funds to accelerate development of inflammatory disease treatments.